Amneal launches boruzu™, first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”), a global biopharmaceutical company, and shilpa medicare limited (“shilpa”) today announced the u.s. launch of boruzu™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (iv) administration. this new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. boruzu™ (bortezomib injection), a pr.
AMRX Ratings Summary
AMRX Quant Ranking